Professional Documents
Culture Documents
29 August 2016 of
Interest on supply of
COVID-19 vaccines
on behalf of the
COVAX Facility
Public version, 31 August 2020
© UNICEF/UNI197921/Schermbrucker
Expression of Interest (EOI) overview
• UNICEF issued an EOI on 15 June 2020 on behalf of the COVAX Facility
• EOI Objectives: Understand manufacturing plans and help inform design elements of the
COVAX Facility and the associated procurement approach
Volumes
in EOI or publicly stated (NB:
Supply
Data unqualified)
18,000,000,000
Global demand scenario, 15,840,000,000
Scenario
Demand
UNICEF
8
Expression of Interest on supply of COVID-19 vaccines
Different lenses on aggregate production
capacity estimates
Indicated annual production volumes from manufacturers with another
WHO prequalified vaccine vs. those without a prequalified vaccine
Potential high dependency on manufacturers that have never taken a vaccine through WHO prequalification (PQ)
16
Doses (Billions)
14
12
10
Production volumes from
manufacturers with NO other
8 WHO PQ vaccine
6 Production volumes from
manufacturers with other WHO
4
PQ vaccine
2
-
2020 June 2021 2021 2022 2023
16.0
Doses (Billions)
14.0
12.0
10.0 India
8.0 France, UK, Switzerland, Russia, Japan
6.0 China
Brazil, US
4.0
2.0
0.0
2020 June 2021 2021 2022 2023
• In 2020, 19% are from mfrs in China; 22% are from mfrs in India
• In 2023, 49% are from China; 22% from India
Doses (Billions)
16
14
12
10
8
6
4
2
-
2020 June 2021 2021 2022 2023
*Indications come from a mixture of EOI responses and information available in the public domain
• Streamlining / harmonizing • Support for enrolment in • More information and • Technical matchmaking (company)
regulatory processes at phase 3 clinical trials (esp dialogue on product specific
national and global level outside of China) presentation • Push/pull funding for adjuvants,
• Accelerated PQ process (ref • Data sharing / cooperation • Acceptance of universal fill/finish capacity
lessons learned from Ebola) between clinical trials packaging in English • Adjuvant matchmaking
• Creation of an emergency use • Clarification on minimum with country specific • Validation of country readiness
pathway level of acceptance for inserts in tertiary • Consultation with industry on CCE
• Support to in-country Phase III clinical trials packaging requirements
registration
Yalda Momeni
Senior COVAX Contracts Manager
Vaccine Centre, UNICEF Supply Division
ymomeni@unicef.org
20